Health Subcommittee, Energy and Commerce Committee
Introduced
In Committee
On Floor
Passed Chamber
Enacted
Creating Hope Reauthorization Act of 2024 This bill extends until FY2029 a Food and Drug Administration program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)
Child healthDrug safety, medical device, and laboratory regulationPrescription drugs
Creating Hope Reauthorization Act of 2024
USA118th CongressHR-7384| House
| Updated: 2/16/2024
Creating Hope Reauthorization Act of 2024 This bill extends until FY2029 a Food and Drug Administration program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)